Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 141

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 141
---
(2)              |     |  48 |     | Director                                              |
| Hon. Cathy McMorris Rodgers     |     |  56 |     | Director                                              |
| Ajay Raju                       |     |  55 |     | Director                                              |
| Patrick J. Mahaffy              |     |  62 |     | Director                                              |
| Dr. Raza Bokhari(3)             |     |  58 |     | Executive Chairman and Chief Executive Officer        |
| Carolyn Bonner                  |     |  41 |     | President and Acting Chief Financial Officer          |
| James Quinlan                   |     |  61 |     | Chief Financial Officer (on medical leave of absence) |
| Dr. Edward Brennan              |     |  65 |     | Chief Scientific Officer & Head of R&D Program        |
| Dr. Faisal Mehmud               |     |  50 |     | Chief Medical Officer                                 |
| Andrew Smith                    |     |  57 |     | Chief Operating Officer                               |

Notes:

(1)Member of the Compensation Committee. Dr. Kaiser is the Chair.

(2)Member of the Audit Committee. Mr. Ciaruffoli is the Chair.

(3)Member of the Corporate Disclosure Committee. Mr. Fishman is the Chair.

(4)Member of the Governance Committee. The Hon. Cathy McMorris Rodgers is the Chair.

(5)Member of the Nominating Committee. Dr. May is the Chair.

Set forth below is a description of the background of the directors and executive officers of Medicus.

Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer

Dr. Bokhari has served as our Executive Chairman and Chief Executive Officer since September 2023. Dr. Bokhari works full time for the Company.

A recipient of Philadelphia Business Journal's "40 under 40" award, Dr. Raza Bokhari, a physician turned serial entrepreneur, has a demonstrated successful track record in aggregating and accelerating life sciences, healthcare services and Pharmaceutical R&D companies.

He previously served as Executive Chairman and CEO of FSD Pharma (Nasdaq: HUGE) (2020 to 2021), where his strategies successfully pivoted the company out of medicinal cannabis and into a clinical stage pharmaceutical R&D, a transition marked by a NASDAQ listing in January 2020, and raising nearly $100M institutional capital to fuel growth and expansion.

<div align='center'>